EC Number   |
Inhibitors |
Structure |
|---|
   3.4.21.47 | 6-amidino-2-naphthyl-4-guanidinobenzoate |
- |
   |
| 3.4.21.47 | Ab (2B7) |
inhibits the deposition of C3b on Escherichia coli in hemolymph plasma, whereas it exhibits no inhibitory effect on the deposition of C3b on Staphylococcus aureus |
|
| 3.4.21.47 | Aurin tricarboxylic acid |
blocks the alternative pathway at a downstream step from C3b attachment. It prevents formation of C3 convertase at the stage where Factor B, attached to the membrane-bound properdin-C3b-Factor B (PC3bB) complex, is cleaved by the protease action of Factor D to form the active C3 convertase enzyme PC3bBb. Activity is restored by the addition of excess Factor D to the serum. But membrane attack complex formation is still blocked by ATA at the stage of C9 addition to C5b678. It has no effect on the classical pathway activation. Binding of aurin tricarboxylic acid to the QPDTIDHDLLLLQLS site blocks the ability of aurin tricarboxylic acid to bind to Factor D protein |
|
| 3.4.21.47 | C3b-specific antibody fragment S77 |
inhibits the alternative pathway C5 convertase in human serum |
|
| 3.4.21.47 | C4BP |
the inhibitor blocks both C3 and C5 conversion |
|
| 3.4.21.47 | complement factor H-related protein 1 |
0.005-0.16 mg/ml inhibits C5 convertase activity |
|
| 3.4.21.47 | complement receptor 1 |
CR1, mediates decay acceleration of the C3bBb complex |
|
| 3.4.21.47 | complement receptor of immunoglobulin family |
the inhibitor blocks both C3 and C5 conversion |
|
| 3.4.21.47 | Cp40 |
the inhibitor blocks both C3 and C5 conversion |
|
| 3.4.21.47 | CRIg |
phagocytic receptor, binds to the beta-chain of complement components C3b and C3c and inhibits the AP C3 and C5 convertases, structure-activity relationship of CRIg mutants indicated |
|
